PriceTargets.com logo

Illumina - ILMN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $128.15
  • Forecasted Upside: 53.03%
  • Number of Analysts: 21
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$83.74 As of 05/21/2025 10:32 AM ET
▼ -0.469 (-0.56%)

This chart shows the closing price for ILMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Illumina Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ILMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ILMN

Analyst Price Target is $128.15
▲ +53.03% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $128.15, with a high forecast of $200.00 and a low forecast of $77.00. The average price target represents a 53.03% upside from the last price of $83.74.

This chart shows the closing price for ILMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 21 contributing investment analysts is to hold stock in Illumina. This rating has held steady since February 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
11/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
2/26/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
5/26/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
8/24/2024
  • 2 strong buy ratings
  • 13 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/22/2024
  • 2 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
2/20/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
4/21/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
5/21/2025

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/20/2025StephensReiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00
5/15/2025Piper SandlerLower TargetOverweight ➝ Overweight$190.00 ➝ $185.00
5/12/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$136.00 ➝ $100.00
5/12/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$92.00 ➝ $87.00
5/9/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$120.00 ➝ $85.00
5/9/2025GuggenheimLower TargetBuy ➝ Buy$122.00 ➝ $114.00
4/29/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$115.00 ➝ $92.00
4/10/2025BarclaysLower TargetUnderweight ➝ Underweight$100.00 ➝ $77.00
4/8/2025Royal Bank of CanadaLower TargetOutperform ➝ Outperform$128.00 ➝ $112.00
4/7/2025CitigroupLower TargetNeutral ➝ Neutral$90.00 ➝ $85.00
3/12/2025Royal Bank of CanadaLower TargetOutperform ➝ Outperform$247.00 ➝ $128.00
3/11/2025BarclaysReiterated RatingUnderweight ➝ Underweight
3/11/2025StephensReiterated RatingOverweight ➝ Overweight$156.00 ➝ $156.00
3/11/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$135.00 ➝ $115.00
3/5/2025Robert W. BairdLower TargetNeutral ➝ Neutral$127.00 ➝ $90.00
3/4/2025CitigroupLower TargetNeutral ➝ Neutral$130.00 ➝ $90.00
2/28/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
2/28/2025HSBCDowngradeBuy ➝ Hold$100.00
2/11/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$150.00 ➝ $136.00
2/10/2025Piper SandlerBoost TargetOverweight ➝ Overweight$185.00 ➝ $190.00
2/10/2025BarclaysDowngradeEqual Weight ➝ Underweight$130.00 ➝ $100.00
2/7/2025Royal Bank of CanadaLower TargetOutperform ➝ Outperform$250.00 ➝ $247.00
2/7/2025Canaccord Genuity GroupLower TargetHold ➝ Hold$145.00 ➝ $135.00
2/7/2025GuggenheimLower TargetBuy ➝ Buy$170.00 ➝ $150.00
2/7/2025TD CowenDowngradeBuy ➝ Hold$177.00 ➝ $140.00
2/3/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$145.00 ➝ $130.00
1/13/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$156.00 ➝ $150.00
12/11/2024CitigroupDowngradeBuy ➝ Neutral$190.00 ➝ $165.00
11/12/2024StephensBoost TargetOverweight ➝ Overweight$170.00 ➝ $184.00
11/12/2024Morgan StanleyReiterated RatingEqual Weight$156.00
11/11/2024Piper SandlerLower TargetOverweight ➝ Overweight$195.00 ➝ $185.00
11/6/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$124.00 ➝ $139.00
11/5/2024TD CowenBoost TargetBuy ➝ Buy$166.00 ➝ $177.00
11/5/2024UBS GroupBoost TargetNeutral ➝ Neutral$133.00 ➝ $145.00
11/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$252.00 ➝ $254.00
11/5/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$125.00 ➝ $140.00
11/5/2024CitigroupBoost TargetBuy ➝ Buy$155.00 ➝ $190.00
11/5/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$135.00 ➝ $145.00
11/5/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$130.00 ➝ $145.00
10/17/2024Hsbc Global ResUpgradeHold ➝ Strong-Buy$180.00
10/17/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$160.00 ➝ $200.00
10/17/2024HSBCUpgradeHold ➝ Buy$180.00
10/15/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$125.00 ➝ $135.00
10/10/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$252.00 ➝ $252.00
8/28/2024ArgusUpgradeHold ➝ Buy$150.00
8/16/2024Daiwa AmericaUpgradeStrong-Buy
8/16/2024Daiwa Capital MarketsUpgradeNeutral ➝ Buy$120.00 ➝ $154.00
8/15/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$176.00 ➝ $164.00
8/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$242.00 ➝ $242.00
8/14/2024TD CowenUpgradeHold ➝ Buy$126.00 ➝ $144.00
8/14/2024BarclaysUpgradeUnderweight ➝ Equal Weight$125.00
8/13/2024Piper SandlerLower TargetOverweight ➝ Overweight$200.00 ➝ $195.00
8/7/2024TD CowenBoost TargetHold ➝ Hold$122.00 ➝ $126.00
8/7/2024CitigroupBoost TargetBuy ➝ Buy$140.00 ➝ $155.00
8/7/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$130.00 ➝ $125.00
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$242.00 ➝ $242.00
8/7/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$119.00 ➝ $124.00
8/7/2024UBS GroupBoost TargetNeutral ➝ Neutral$131.00 ➝ $133.00
7/10/2024StephensReiterated RatingOverweight ➝ Overweight$170.00 ➝ $170.00
7/10/2024CitigroupUpgradeNeutral ➝ Buy$140.00
7/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$249.00 ➝ $242.00
6/11/2024Evercore ISILower TargetOutperform ➝ Outperform$195.00 ➝ $175.00
6/6/2024TD CowenLower TargetHold ➝ Hold$140.00 ➝ $122.00
6/3/2024Jefferies Financial GroupInitiated CoverageHold$115.00
5/7/2024StephensReiterated RatingOverweight ➝ Overweight$170.00
5/6/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$185.00 ➝ $176.00
5/3/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$125.00 ➝ $128.00
4/10/2024BarclaysBoost TargetUnderweight ➝ Underweight$85.00 ➝ $100.00
4/10/2024StephensReiterated RatingOverweight ➝ Overweight$170.00
4/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$253.00
3/20/2024OTR GlobalReiterated RatingPositive ➝ Mixed
2/14/2024StephensReiterated RatingOverweight ➝ Overweight$170.00
2/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$258.00
1/25/2024BarclaysBoost TargetUnderweight ➝ Underweight$50.00 ➝ $80.00
1/16/2024HSBCDowngradeBuy ➝ Hold
1/4/2024TD CowenDowngradeOutperform ➝ Market Perform$144.00
12/19/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$260.00 ➝ $258.00
12/18/2023ScotiabankUpgradeSector Perform ➝ Sector Outperform$185.00
12/15/2023Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
12/14/2023StephensInitiated CoverageOverweight$170.00
12/14/2023GuggenheimInitiated CoverageBuy$155.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$175.00
12/12/2023Bank of AmericaDowngradeNeutral ➝ Underperform$140.00 ➝ $100.00
12/11/2023CitigroupUpgradeSell ➝ Neutral$85.00 ➝ $120.00
11/13/2023Piper SandlerLower TargetOverweight ➝ Overweight$200.00 ➝ $190.00
11/10/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$210.00 ➝ $120.00
11/10/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$210.00 ➝ $120.00
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$275.00 ➝ $200.00
10/12/2023Stifel NicolausReiterated RatingBuy ➝ Buy$200.00
9/29/2023Stifel NicolausLower TargetBuy ➝ Buy$225.00 ➝ $200.00
9/29/2023BarclaysLower TargetUnderweight ➝ Underweight$150.00 ➝ $100.00
9/29/2023HSBCLower Target$230.00 ➝ $171.00
9/28/2023Sanford C. BernsteinInitiated CoverageUnderperform$111.00
9/1/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$240.00
8/16/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$300.00 ➝ $285.00
8/15/2023Piper SandlerLower TargetOverweight ➝ Overweight$290.00 ➝ $275.00
8/14/2023HSBCLower TargetBuy ➝ Buy$270.00 ➝ $235.00
8/10/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$235.00 ➝ $190.00
8/10/2023Evercore ISIBoost TargetOutperform ➝ Outperform$235.00 ➝ $240.00
8/10/2023Stifel NicolausLower TargetBuy ➝ Buy$265.00 ➝ $225.00
8/10/2023Bank of AmericaLower Target$230.00 ➝ $210.00
8/10/2023CitigroupLower TargetSell ➝ Sell$180.00 ➝ $150.00
8/10/2023Credit Suisse GroupLower TargetNeutral ➝ Neutral$225.00 ➝ $200.00
8/10/2023Robert W. BairdLower Target$229.00 ➝ $180.00
8/8/2023UBS GroupLower TargetNeutral ➝ Neutral$240.00 ➝ $230.00
8/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$337.00 ➝ $328.00
4/26/2023Stifel NicolausBoost Target$235.00 ➝ $265.00
4/26/2023Robert W. BairdBoost Target$224.00 ➝ $229.00
4/14/2023Royal Bank of CanadaBoost TargetOutperform$300.00 ➝ $337.00
3/15/2023Royal Bank of CanadaLower TargetOutperform$303.00 ➝ $300.00
2/14/2023UBS GroupLower TargetNeutral$255.00 ➝ $240.00
2/8/2023Piper SandlerReiterated RatingOverweight$290.00
2/8/2023Stifel NicolausLower Target$285.00 ➝ $235.00
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$300.00 ➝ $271.00
2/8/2023Royal Bank of CanadaBoost TargetOutperform$284.00 ➝ $303.00
2/8/2023Bank of AmericaBoost Target$210.00 ➝ $230.00
2/8/2023Leerink PartnersBoost TargetOutperform$249.00 ➝ $250.00
2/8/2023BarclaysLower TargetUnderweight$160.00 ➝ $150.00
1/27/2023Piper SandlerLower Target$300.00 ➝ $290.00
1/25/2023ArgusDowngradeBuy ➝ Hold
1/17/2023Canaccord Genuity GroupLower TargetBuy$330.00 ➝ $300.00
1/10/2023Bank of AmericaLower Target$220.00 ➝ $210.00
1/10/2023CowenLower Target$350.00 ➝ $296.00
1/4/2023ScotiabankInitiated CoverageSector Perform$216.00
12/20/2022OTR GlobalUpgradeMixed ➝ Positive
12/12/2022CitigroupDowngradeNeutral ➝ Sell$200.00 ➝ $180.00
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$282.00
11/14/2022Piper SandlerLower TargetOverweight$320.00 ➝ $300.00
11/7/2022Morgan StanleyLower TargetEqual Weight$240.00 ➝ $225.00
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$340.00 ➝ $330.00
11/4/2022CowenBoost Target$327.00 ➝ $350.00
11/4/2022Credit Suisse GroupLower TargetNeutral$230.00 ➝ $225.00
11/4/2022CowenBoost Target$327.00 ➝ $350.00
11/4/2022Robert W. BairdLower Target$215.00 ➝ $210.00
10/11/2022ArgusLower Target$300.00 ➝ $250.00
10/4/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$220.00 ➝ $270.00
9/30/2022BarclaysBoost TargetUnderweight$130.00 ➝ $175.00
9/28/2022OTR GlobalDowngradePositive
9/28/2022Evercore ISIUpgradeIn-Line ➝ Outperform$170.00 ➝ $250.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$230.00
8/17/2022UBS GroupLower TargetNeutral$350.00 ➝ $245.00
8/15/2022Evercore ISILower Target$170.00
8/15/2022CowenLower Target$327.00
8/15/2022BarclaysLower Target$130.00
8/15/2022Atlantic SecuritiesLower Target$190.00
8/12/2022Morgan StanleyLower TargetEqual Weight$350.00 ➝ $240.00
8/12/2022Bank of AmericaLower Target$220.00 ➝ $200.00
8/12/2022Piper SandlerLower TargetOverweight$360.00 ➝ $320.00
8/12/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$450.00 ➝ $380.00
8/12/2022Leerink PartnersLower TargetMarket Perform$225.00 ➝ $220.00
8/12/2022Stifel NicolausLower TargetBuy$480.00 ➝ $300.00
8/12/2022CitigroupLower TargetNeutral$220.00 ➝ $200.00
8/12/2022Robert W. BairdLower Target$306.00 ➝ $215.00
7/19/2022CowenSet Target$412.00
7/13/2022BarclaysDowngradeEqual Weight ➝ Underweight$350.00 ➝ $150.00
7/8/2022CitigroupLower TargetNeutral$325.00 ➝ $220.00
5/15/2022Piper SandlerLower TargetNA$460.00 ➝ $360.00
5/6/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$555.00 ➝ $520.00
5/6/2022CowenLower Target$506.00 ➝ $492.00
5/6/2022CowenLower Target$506.00 ➝ $492.00
5/6/2022CitigroupLower Target$400.00 ➝ $325.00
3/29/2022OTR GlobalUpgradeMixed ➝ Positive
2/15/2022Piper SandlerBoost TargetOverweight$450.00 ➝ $460.00
2/11/2022Robert W. BairdLower Target$437.00 ➝ $380.00
2/11/2022Leerink PartnersLower TargetMarket Perform$430.00 ➝ $400.00
1/18/2022Stifel NicolausUpgradeHold ➝ Buy$480.00
1/11/2022BarclaysUpgradeUnderweight ➝ Equal Weight$432.72 ➝ $412.00
1/11/2022Leerink PartnersBoost TargetMarket Perform$420.00 ➝ $430.00
1/10/2022BarclaysLower TargetUnderweight$365.00 ➝ $350.00
1/7/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$390.00
1/6/2022CitigroupLower TargetNeutral ➝ Neutral$450.00 ➝ $400.00
1/6/2022Morgan StanleyInitiated CoverageNeutral ➝ Equal Weight$425.00
11/8/2021Robert W. BairdLower TargetNeutral$493.00 ➝ $437.00
10/19/2021Leerink PartnersLower TargetMarket Perform$425.00 ➝ $420.00
8/22/2021Robert W. BairdReiterated RatingHold
8/19/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$425.00
8/6/2021BarclaysBoost TargetUnderweight$355.00 ➝ $365.00
8/6/2021Piper SandlerBoost TargetOverweight$510.00 ➝ $560.00
7/29/2021Leerink PartnersReiterated RatingBuy
7/13/2021BarclaysBoost TargetUnderweight$300.00 ➝ $355.00
4/28/2021Wells Fargo & CompanyBoost TargetUnderweight$330.00 ➝ $340.00
4/6/2021Wells Fargo & CompanyBoost TargetUnderweight$300.00 ➝ $330.00
3/31/2021Atlantic SecuritiesDowngradeOverweight ➝ Neutral$390.00
3/2/2021BarclaysInitiated CoverageUnderweight$325.00
2/16/2021BTIG ResearchBoost TargetBuy$410.00 ➝ $570.00
2/12/2021Piper SandlerBoost TargetOverweight$415.00 ➝ $510.00
2/12/2021CowenBoost TargetOutperform$385.00 ➝ $460.00
2/12/2021Leerink PartnersBoost TargetOutperform$360.00 ➝ $470.00
12/22/2020OTR GlobalUpgradePositive
12/22/2020Piper SandlerUpgradeNeutral ➝ Overweight$340.00 ➝ $415.00
12/17/2020BTIG ResearchUpgradeNeutral ➝ Buy$410.00
12/16/2020Smith Barney CitigroupBoost Target$330.00 ➝ $335.00
12/7/2020Leerink PartnersBoost TargetPositive ➝ Outperform$325.00 ➝ $360.00
12/1/2020ArgusLower Target$380.00 ➝ $355.00
10/30/2020Leerink PartnersBoost TargetOutperform$315.00 ➝ $325.00
10/13/2020GuggenheimDowngradeBuy ➝ Neutral
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$355.00 ➝ $355.00
9/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer Perform
9/22/2020Robert W. BairdLower TargetNeutral$335.00 ➝ $281.00
9/22/2020Leerink PartnersLower TargetOutperform$360.00 ➝ $315.00
9/22/2020Stifel NicolausDowngradeBuy ➝ Hold$380.00 ➝ $280.00
9/22/2020UBS GroupDowngradeBuy ➝ Neutral$390.00 ➝ $285.00
9/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$390.00 ➝ $280.00
9/21/2020GuggenheimUpgradeNeutral ➝ Buy$345.00
9/11/2020ArgusReiterated RatingBuy ➝ Reduce$380.00 ➝ $380.00
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$400.00
8/7/2020Leerink PartnersLower TargetOutperform$370.00 ➝ $360.00
8/7/2020Evercore ISIDowngradeIn-Line ➝ Underperform$310.00
8/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$356.00 ➝ $340.00
7/7/2020GuggenheimDowngradeBuy ➝ Neutral
7/2/2020JPMorgan Chase & Co.Boost TargetOverweight$340.00 ➝ $390.00
5/21/2020ArgusBoost Target$340.00 ➝ $380.00
(Data available from 5/21/2020 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 26 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 46 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 56 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
12/22/2024
  • 15 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2025
  • 50 very positive mentions
  • 41 positive mentions
  • 20 negative mentions
  • 3 very negative mentions
Mentions as of
2/20/2025
  • 56 very positive mentions
  • 45 positive mentions
  • 18 negative mentions
  • 5 very negative mentions
Mentions as of
3/22/2025
  • 87 very positive mentions
  • 23 positive mentions
  • 12 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2025
  • 71 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
5/21/2025

Current Sentiment

  • 71 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Illumina logo
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Read More

Today's Range

Now: $83.74
Low: $84.10
High: $84.10

50 Day Range

MA: $78.46
Low: $70.30
High: $88.02

52 Week Range

Now: $83.74
Low: $68.70
High: $156.66

Volume

6,382 shs

Average Volume

2,434,673 shs

Market Capitalization

$13.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?

The following Wall Street sell-side analysts have issued research reports on Illumina in the last year: Argus, Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Daiwa America, Daiwa Capital Markets, Evercore ISI, Guggenheim, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stephens, StockNews.com, TD Cowen, and UBS Group AG.
View the latest analyst ratings for ILMN.

What is the current price target for Illumina?

0 Wall Street analysts have set twelve-month price targets for Illumina in the last year. Their average twelve-month price target is $128.15, suggesting a possible upside of 52.2%. Leerink Partners has the highest price target set, predicting ILMN will reach $200.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $77.00 for Illumina in the next year.
View the latest price targets for ILMN.

What is the current consensus analyst rating for Illumina?

Illumina currently has 1 sell rating, 10 hold ratings, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ILMN, but not buy more shares or sell existing shares.
View the latest ratings for ILMN.

What other companies compete with Illumina?

Other companies that are similar to Illumina include Agilent Technologies, Mettler-Toledo International, Waters, Bio-Techne and Bio-Rad Laboratories. Learn More about companies similar to Illumina.

How do I contact Illumina's investor relations team?

Illumina's physical mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company's listed phone number is (858) 202-4500 and its investor relations email address is [email protected]. The official website for Illumina is www.illumina.com. Learn More about contacing Illumina investor relations.